BR0108411A - Formulação contraceptiva masculina compreendendo noretisterona - Google Patents

Formulação contraceptiva masculina compreendendo noretisterona

Info

Publication number
BR0108411A
BR0108411A BR0108411-9A BR0108411A BR0108411A BR 0108411 A BR0108411 A BR 0108411A BR 0108411 A BR0108411 A BR 0108411A BR 0108411 A BR0108411 A BR 0108411A
Authority
BR
Brazil
Prior art keywords
norethisterone
male contraceptive
contraceptive formulation
testosterone
men
Prior art date
Application number
BR0108411-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Eberhard Nieschlag
Axel Kamischke
Michael Oettel
Alexander Ruebig
Ekkerhard Schillinger
Ursula-Friederike Habenicht
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0108411A publication Critical patent/BR0108411A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR0108411-9A 2000-02-15 2001-02-15 Formulação contraceptiva masculina compreendendo noretisterona BR0108411A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50372900A 2000-02-15 2000-02-15
EP00200493 2000-02-15
PCT/IB2001/000188 WO2001060376A1 (en) 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone

Publications (1)

Publication Number Publication Date
BR0108411A true BR0108411A (pt) 2003-03-11

Family

ID=26071832

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108411-9A BR0108411A (pt) 2000-02-15 2001-02-15 Formulação contraceptiva masculina compreendendo noretisterona

Country Status (26)

Country Link
EP (2) EP1267885B8 (enExample)
JP (1) JP2003522795A (enExample)
KR (1) KR20020086905A (enExample)
CN (1) CN1423560A (enExample)
AT (2) ATE474580T1 (enExample)
AU (1) AU2001230447A1 (enExample)
BG (1) BG107066A (enExample)
BR (1) BR0108411A (enExample)
CA (1) CA2398063A1 (enExample)
CY (1) CY1106639T1 (enExample)
CZ (1) CZ20022691A3 (enExample)
DE (2) DE60142647D1 (enExample)
DK (1) DK1267885T3 (enExample)
EE (1) EE200200454A (enExample)
ES (1) ES2282230T3 (enExample)
HK (1) HK1049442B (enExample)
HU (1) HUP0300128A3 (enExample)
IL (1) IL151219A0 (enExample)
MX (1) MXPA02007675A (enExample)
NO (1) NO20023607L (enExample)
PL (1) PL357185A1 (enExample)
PT (1) PT1267885E (enExample)
RU (1) RU2002124602A (enExample)
SI (1) SI1267885T1 (enExample)
SK (1) SK11602002A3 (enExample)
WO (1) WO2001060376A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
JP4417838B2 (ja) 2002-07-24 2010-02-17 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 7α−置換された11α−ヒドロキシステロイドの微生物的生成方法
BR0312922A (pt) * 2002-07-25 2005-07-12 Schering Ag Composição contendo um androgênio 11 beta halogênio-esteróide e um gestagênio assim como um contraceptivo masculino à base dessa composição
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN101352443B (zh) * 2007-07-23 2011-01-12 中国科学院动物研究所 哺乳动物雄性不育剂
CN112074269A (zh) 2018-03-23 2020-12-11 美卓实验室 用于男性避孕的非激素组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714420A1 (de) * 1976-06-01 1977-12-08 Int Pregnancy Advisory Service Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
DE19650352A1 (de) * 1996-12-04 1998-07-30 Jenapharm Gmbh Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann

Also Published As

Publication number Publication date
HUP0300128A2 (en) 2003-05-28
DE60127103T2 (de) 2007-11-22
DK1267885T3 (da) 2007-07-09
HK1049442B (en) 2007-06-15
RU2002124602A (ru) 2004-03-10
NO20023607D0 (no) 2002-07-30
EE200200454A (et) 2003-12-15
ATE355844T1 (de) 2007-03-15
SK11602002A3 (sk) 2003-03-04
CA2398063A1 (en) 2001-08-23
DE60127103D1 (de) 2007-04-19
HK1049442A1 (en) 2003-05-16
ATE474580T1 (de) 2010-08-15
EP1666044B1 (en) 2010-07-21
KR20020086905A (ko) 2002-11-20
PL357185A1 (en) 2004-07-26
CY1106639T1 (el) 2012-01-25
AU2001230447A1 (en) 2001-08-27
HUP0300128A3 (en) 2004-03-29
EP1267885B8 (en) 2007-06-20
WO2001060376A1 (en) 2001-08-23
SI1267885T1 (sl) 2007-08-31
ES2282230T3 (es) 2007-10-16
CN1423560A (zh) 2003-06-11
NO20023607L (no) 2002-10-15
EP1267885B1 (en) 2007-03-07
EP1267885A1 (en) 2003-01-02
JP2003522795A (ja) 2003-07-29
EP1666044A1 (en) 2006-06-07
CZ20022691A3 (cs) 2003-01-15
IL151219A0 (en) 2003-04-10
DE60142647D1 (de) 2010-09-02
PT1267885E (pt) 2007-05-31
MXPA02007675A (es) 2004-02-26
BG107066A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
GEP20053586B (en) Selective Androgen Receptor Modulators and Pharmaceutical Compositions Containing the Same
CY1106639T1 (el) Τυποποιηση αντισυλληπτικου για ανδρες που περιλαμβανει νορεθιστερονη
NO20032805D0 (no) Preparater av östrogensyklodekstrinkomplekser
HK1056181A1 (zh) 作為抗炎劑的17β-硫代羧酸酯17α-芳基羰氧基氧雄甾烷衍生物
AR073972A2 (es) Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas
IN2012DN04867A (enExample)
WO2001068074A3 (en) Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
DE59510887D1 (de) Feste arzneiformen, enthaltend clathrate vom steroidalen sexualhormon ethinylestradiol
HUP0200173A2 (en) Combined use of estrogen and progestogen, norethindrone acetate and ethinyl estradiol for preparing pharmaceutical compositions for preventing and treating skin aging and acne
CA2467237A1 (en) Method of preventing or treating benign gynaecological disorders
ATE225800T1 (de) Nichtestrogene derivate des estradiols mit antioxidativer aktivität
WO2004006936A8 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
WO2002042319A3 (en) 2-substituted estrogens as antiangiogenic agents
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
WO2001040255A3 (en) 14,15-beta-methylene substituted androgens
AR027526A1 (es) Formulacion anticonceptiva masculina que comprende noretisterona
JP2003522795A5 (enExample)
AU1047002A (en) 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
AR048829A1 (es) 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos.
CO6270329A2 (es) Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa
PL1910398T3 (pl) 17-alfa-podstawione pochodne estradiolu wykazujące działanie gojenia ran

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008.